|
Lavipharm is an integrated Group of
companies engaged in the research, development,
production, import, marketing,
sales, and logistics services of pharmaceutical,
dermocosmetic and healthcare
products in Greece with a strong international
activity.
LAVIPHARM's plant is considered as one
of the few in Greece with fully integrated
production lines for solid and liquid pharmaceutical
forms, transdermal delivery
systems, epidermal cosmetic patches, creams
and lotions. With operations
throughout Greece, France, Cyprus and
the United States of America, LAVIPHARM
cooperates with well-known international
pharmaceutical and cosmetic companies.
Lavipharm Laboratories, LAVIPHARM's
R&D arm in the U.S.A., spearheads both
the development and marketing of its
international products. The company's
mission is to link innovative drug delivery
discovery and product formulation
technology with molecule transport,
providing integrated development services
from design phase to commercialisation.
It achieves this with its unique solubilisation
technologies and with a range of
innovative delivery systems developed in -
house.
LAVIPHARM's first international product is
a transdermal system that is smaller, thinner
and esthetically superior to the ones
already in the market. LAVIPHARM's
once-a-day matrix transdermal patch of
nitroglycerine for the treatment of angina
is marketed in France, Italy, Belgium,
Holland, Spain and Greece and since
2006 in Canada.
LAVIPHARM has also entered into feasibility
and/or development agreements with
a number of companies in Europe and the
U.S. for the development of products utilising
its proprietary technology platforms.
The pharmaceutical product most recently
developed by Lavipharm Laboratories and
already approved by the US Food & Drug
Administration is a new generation generic
fentanyl patch.
Lavipharm develops and markets pharmaceutical
products that incorporate its proprietary
technologies, such as several
delivery systems, including matrix patches
and liquid reservoir patches. On August 7,
2006, Lavipharm announced the approval
to market its generic fentanyl transdermal
system from the FDA (Food and Drug
Administration). The product has been
developed by Lavipharm Laboratories,
Inc., the Group's R&D arm in the U.S.
LAVIPHARM's current R&D activities are
concentrated on the following fields:
- Super Critical Fluid Applications
- Drug Delivery Systems
- Cosmetic Delivery Systems
Longer term R&D activities include:
- Focusing and Capitalization on the
company's existing technologies.
- Expansion to related technologies alone
or in collaboration with Scientists,
Institutes and Research companies.
- Life cycle management and delivery
modification for new off-patent actives.
Lavipharm intends to use its expertise on
a number of SCF processes leading to particle
design, formulations of improved
characteristics, drying and microencapsulation
of proteins and related
products etc.
Lavipharm welcomes outlicensing
opportunities for its already developed
products, as well as co-development
arrangements with partners to develop
new proprietary products. The company
has already fully developed a number of
prototypes, available for license, and has,
in the pipeline, others for further development.
In the field of SCF, Lavipharm is interested
in partnerships with pharmaceutical and
biotechnology companies with molecules
in need of particle design and/or formulation
to address specific requests.
Lavipharm offers comprehensive capabilities
from feasibility to industrial
production, to equipment design and
manufacture, using supercritical fluids
under GMP conditions.
|
|
Tel.: + 30 210 6691200
Fax:+ 30 210 6691209
E-mail:
Web: www.lavipharm.com
Address: Agias Marinas Str. - Peania
19002– Attica - GREECE
|
